News

News

Reveal Biosciences and Science Exchange Apply Artificial Intelligence to Pathology

Science Exchange, the leading marketplace for outsourced R&D™, announces a collaboration with Reveal Biosciences to offer on-demand access to AI-based pathology services worldwide.

Reveal Biosciences is a San Diego-based company that’s leading the next generation of quantitative histopathology, combining the latest artificial intelligence (AI) techniques with high-quality histology, immunohistochemistry (IHC) and in situ hybridization (ISH) to generate enhanced data from tissue samples.

Reveal’s AI-based tissue analysis utilizes trained pathology models to recognize disease patterns in whole slide digital images. This service can be applied to tumor profiling, quantitative immunohistochemistry, NASH, toxicology and quantitative multiplexing. On top of that, Reveal is generating disease-specific AI-based models as pathology decision support tools to accelerate clinical trials for the benefit of patients.

“We are delighted to join forces with Science Exchange,” said Claire Weston, Ph.D., Founder and CEO of Reveal Biosciences. “I am confident that our unique application of artificial intelligence to pathology will benefit Science Exchange’s life sciences community.”

“The use of AI-based tools in pathology is expected to increase significantly over time in both drug discovery and patient diagnostics as it is more cost-effective, accurate, reproducible and scalable,” stated Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Reveal Biosciences is the leader in employing an AI-based approach in the pathology space, and we are thrilled to team up with them.”

About Reveal Biosciences

Reveal Biosciences is a San Diego-based computational pathology company leveraging artificial intelligence (AI) to enable pathologists to make diagnostic decisions faster, more accurately, and for less money. The company also supports drug development by combining traditional histopathology with AI to transform tissue biology into actionable data. Reveal’s portfolio includes in situ hybridization (ISH), immunohistochemistry (IHC), immunofluorescence (IF), histopathology, and whole slide imaging. Follow the company on Twitter @RevealBio, Instagram @RevealBio, Facebook and LinkedIn.

ABOUT THE AUTHOR
author

Gursatya "Guru" Singh

Director of Scientific Content & Marketing

Gursatya Singh, also known as "Guru", manages the development and execution of strategic marketing initiatives to improve platform suppliers’ visibility and user experience. He is a true guru when it comes to helping suppliers better advertise their research services and providing buyers with easy access to recently commercialized external innovations. Whether working as a lab researcher, publishing scientific papers, or helping start life science startups, Guru believes in making the scientific world more collaborative and connected. Guru holds a master’s degree in biotechnology from the University of Delaware. Follow him on Twitter @Gursatya.

Leave a Reply

Your email address will not be published.